Chemomab Therapeutics (CMMB)
NASDAQ:CMMB
Want to see CMMB full AI Analyst Report?
CMMB Stock Chart & Stats
$1.67
-$0.02(-0.88%)
At close: 4:00 PM EST
$1.67
-$0.02(-0.88%)
Day’s Range― - ―
52-Week Range$1.35 - $5.04
Previous CloseN/A
Volume58.22K
Average Volume (3M)207.96K
Market Cap
$11.88M
Enterprise Value$6.40M
Total Cash (Recent Filing)$10.37M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Aug 07, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.46
Shares Outstanding7,192,266
10 Day Avg. Volume363,095
30 Day Avg. Volume207,955
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.85
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.67
Forecast
1Y Price Target
$15.00Price Target Upside798.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Minimal DebtChemomab’s minimal debt position is a durable financial strength for a pre-revenue biotech. Low leverage reduces interest burdens, preserves flexibility to structure non-dilutive deals or staged financings, and lessens bankruptcy risk if capital markets tighten during multi-year clinical development.
Streamlined FDA Path To Registrational TrialAgreement with the FDA on a single Phase 3 pathway materially de-risks development timing and design. A streamlined registrational plan reduces incremental regulatory uncertainty and cost, improving the odds of efficient approval and strengthening the company’s negotiating position with partners over the next 2–6 months and beyond.
Compelling Phase 2 Biomarker & Mechanistic DataRobust biomarker and mechanistic evidence supports nebokitug’s disease-modifying hypothesis in PSC and PSC–IBD. Durable scientific validation increases partner interest, aids regulatory discussions, and supports patient stratification strategies—strengthening commercial and clinical positioning ahead of pivotal studies.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow is a structural weakness: it necessitates regular external financing to fund trials and operations. This ongoing burn creates runway uncertainty, can force financings on unfavorable terms, and constrains long-term planning absent partner deals or capital raises.
Pre-revenue With Recurring LossesBeing pre-revenue after multiple years of development leaves the company dependent on pipeline success to ever generate sustainable cash flow. Recurring losses mean value creation hinges entirely on clinical outcomes and approvals, increasing binary outcome risk for investors and limiting internal reinvestment capacity.
Authorized Capital Increase And Equity Decline RiskApproval to increase authorized share capital is a structural enabler of future equity issuance. Coupled with documented declines in equity and total assets in recent years, this raises durable dilution risk: the company can access equity markets but may erode existing ownership and negotiating leverage in future financings.
Chemomab Therapeutics News
CMMB FAQ
What was Chemomab Therapeutics’s price range in the past 12 months?
Chemomab Therapeutics lowest stock price was $1.35 and its highest was $5.04 in the past 12 months.
What is Chemomab Therapeutics’s market cap?
Chemomab Therapeutics’s market cap is $11.88M.
When is Chemomab Therapeutics’s upcoming earnings report date?
Chemomab Therapeutics’s upcoming earnings report date is Aug 07, 2026 which is in 54 days.
How were Chemomab Therapeutics’s earnings last quarter?
Chemomab Therapeutics released its earnings results on May 14, 2026. The company reported -$0.003 earnings per share for the quarter, missing the consensus estimate of $0 by -$0.003.
Is Chemomab Therapeutics overvalued?
According to Wall Street analysts Chemomab Therapeutics’s price is currently Undervalued.
Does Chemomab Therapeutics pay dividends?
Chemomab Therapeutics does not currently pay dividends.
What is Chemomab Therapeutics’s EPS estimate?
Chemomab Therapeutics’s EPS estimate is 0.
How many shares outstanding does Chemomab Therapeutics have?
Chemomab Therapeutics has 7,192,266 shares outstanding.
What happened to Chemomab Therapeutics’s price movement after its last earnings report?
Chemomab Therapeutics reported an EPS of -$0.003 in its last earnings report, missing expectations of $0. Following the earnings report the stock price went down -2.299%.
Which hedge fund is a major shareholder of Chemomab Therapeutics?
Currently, no hedge funds are holding shares in CMMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chemomab Therapeutics
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
CMMB Stock 12 Month Forecast
Average Price Target
$15.00
▲(798.20% Upside)
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---